FR2793414B1 - Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules - Google Patents
Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellulesInfo
- Publication number
- FR2793414B1 FR2793414B1 FR9905943A FR9905943A FR2793414B1 FR 2793414 B1 FR2793414 B1 FR 2793414B1 FR 9905943 A FR9905943 A FR 9905943A FR 9905943 A FR9905943 A FR 9905943A FR 2793414 B1 FR2793414 B1 FR 2793414B1
- Authority
- FR
- France
- Prior art keywords
- nucleic acid
- cells
- antibody conjugate
- delivering foreign
- foreign nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905943A FR2793414B1 (fr) | 1999-05-10 | 1999-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
EP00925426A EP1175498A2 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
AU44152/00A AU4415200A (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
JP2000616728A JP2002543810A (ja) | 1999-05-10 | 2000-05-10 | 外来性核酸を細胞に送達するための核酸−抗体複合体 |
IL14639900A IL146399A0 (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
PCT/FR2000/001259 WO2000067697A2 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
CA002373851A CA2373851A1 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905943A FR2793414B1 (fr) | 1999-05-10 | 1999-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2793414A1 FR2793414A1 (fr) | 2000-11-17 |
FR2793414B1 true FR2793414B1 (fr) | 2003-05-23 |
Family
ID=9545418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9905943A Expired - Fee Related FR2793414B1 (fr) | 1999-05-10 | 1999-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1175498A2 (fr) |
JP (1) | JP2002543810A (fr) |
AU (1) | AU4415200A (fr) |
CA (1) | CA2373851A1 (fr) |
FR (1) | FR2793414B1 (fr) |
IL (1) | IL146399A0 (fr) |
WO (1) | WO2000067697A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1592412A1 (fr) * | 2003-01-31 | 2005-11-09 | Novartis AG | Regulation negative d'un gene cible a l'aide de complexes de pei/oligoribonucleotide simple brin |
JP4521519B2 (ja) * | 2003-05-26 | 2010-08-11 | 学校法人慶應義塾 | 部分ヒストンテイル型イムノポーター |
FR2958645B1 (fr) * | 2010-04-09 | 2012-08-31 | Commissariat Energie Atomique | Hemi-anticorps a auto-assemblage |
US10540907B2 (en) | 2014-07-31 | 2020-01-21 | Intelligent Technologies International, Inc. | Biometric identification headpiece system for test taking |
US10410535B2 (en) | 2014-08-22 | 2019-09-10 | Intelligent Technologies International, Inc. | Secure testing device |
CN106662746B (zh) | 2014-08-22 | 2020-10-23 | 国际智能技术公司 | 安全考试设备、系统和方法 |
US10438106B2 (en) | 2014-11-04 | 2019-10-08 | Intellignet Technologies International, Inc. | Smartcard |
CN108530540B (zh) * | 2018-03-30 | 2021-06-15 | 华南农业大学 | 抗亚精胺单克隆抗体杂交瘤细胞株4e4及其单克隆抗体和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
WO1988008854A1 (fr) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Anticorps monoclonaux contre le carcinome des cellules renales |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
IL106760A (en) * | 1992-08-25 | 1999-12-31 | Miles Inc | Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
DE69521331T2 (de) * | 1994-11-01 | 2001-09-20 | Winfried Wels | Nukleinsäure-einbringungssystem |
GB9614699D0 (en) * | 1996-07-12 | 1996-09-04 | John P Robarts Research Inst T | Hybrid herpes virus-based vector for gene delivery and expression |
DE19717904A1 (de) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
JP2002511857A (ja) * | 1997-06-11 | 2002-04-16 | ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン | 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物 |
-
1999
- 1999-05-10 FR FR9905943A patent/FR2793414B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-10 CA CA002373851A patent/CA2373851A1/fr not_active Abandoned
- 2000-05-10 JP JP2000616728A patent/JP2002543810A/ja active Pending
- 2000-05-10 IL IL14639900A patent/IL146399A0/xx unknown
- 2000-05-10 AU AU44152/00A patent/AU4415200A/en not_active Abandoned
- 2000-05-10 WO PCT/FR2000/001259 patent/WO2000067697A2/fr active Search and Examination
- 2000-05-10 EP EP00925426A patent/EP1175498A2/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000067697A3 (fr) | 2001-06-28 |
JP2002543810A (ja) | 2002-12-24 |
IL146399A0 (en) | 2002-07-25 |
EP1175498A2 (fr) | 2002-01-30 |
AU4415200A (en) | 2000-11-21 |
WO2000067697A2 (fr) | 2000-11-16 |
CA2373851A1 (fr) | 2000-11-16 |
FR2793414A1 (fr) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1203008A4 (fr) | Ligands acide nucleique reactifs vis-a-vis de ligand cd40 | |
IT1293509B1 (it) | Addensanti per composizioni acquose acide | |
DE60037370D1 (de) | Sinusförmiges Zellkulturmodul zur Kultivierung von Hepatozyten | |
MA25530A1 (fr) | Les diaminothiazoles et leur utilisaion pour inhiber les proteines-kinases. | |
NO20015828D0 (no) | Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater | |
FR2763943B1 (fr) | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules | |
FR2798037B1 (fr) | Cultivateur pour la culture du sol | |
FR2793414B1 (fr) | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules | |
HUP0202221A3 (en) | Tenascin-c nucleic acid lagands | |
CY2010007I1 (el) | Προσδιορισμος in vivo δια την δοκιμασιαν της φαινοτυπικης σταθepοτητος | |
NO20004855D0 (no) | Faststoff elektrolytisk celle | |
EP1225224A4 (fr) | Adn reagissant a la contrainte de cisaillement | |
FR2798939B1 (fr) | Reduction du cokage dans les reacteurs de craquage | |
FR2791673B1 (fr) | Procede de preparation des esters de l'acide hydroxymethylthiobutyrique | |
FR2769855B1 (fr) | Compositions destinees a la culture en sol de fertilite reduite | |
FI19992477A (fi) | Menetelmä konjugoidun linolihapon valmistamiseksi | |
FR2798826B1 (fr) | Filtre pour narguile | |
FR2765482B1 (fr) | Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif | |
GB9913457D0 (en) | Improvements relating to piles | |
GB0018054D0 (en) | Improvements to ploughs | |
FR2807642B1 (fr) | Ameliorations introduites dans les catheters pour l'insemination artificielle des lapines | |
GB2355437B (en) | Improvements relating to anchorages | |
GB0018020D0 (en) | Improvements to ploughs | |
GB2356282B (en) | Improvements relating to maps | |
FR2812305B1 (fr) | Element d'adn promoteur de l'activite de transcription, actif dans les cellules humaines et methode generale pour en ajuster l'activite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20160129 |